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Abstract: Dementia has become a common diagnosis in aging populations, and the numbers 
will increase in the forthcoming years. Alzheimer’s disease (AD) is the most common form 
of dementia in the elderly, accounting for 50%–56% of cases at autopsy and in clinical series. 
Nowadays, the number of people affected by AD is rapidly increasing, and more than 35 million 
people worldwide have AD, a condition characterized by deterioration of memory and other 
cognitive domains, and leading to death 3–9 years after diagnosis. The number of patients with 
AD, the most common cause of disability in the elderly, is set to rise dramatically. Therefore, 
it is important for clinicians to recognize early signs and symptoms of dementia and to note 
potentially modifiable risk factors and early disease markers.
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Introduction
Age is the most important risk factor for AD, with the prevalence rising substantially 
between the ages of 65 and 85 years.1 The incidence of the disease doubles every five 
years after 65 years of age, with diagnosis of 1275 new cases per year per 100,000 
persons older than 65 years, so that AD affects 30%–50% of all people by the age 
of 85 years.2 Data on centenarians show that AD is not necessarily the outcome 
of aging, but the odds of receiving a diagnosis of AD after 85 years exceed one in 
three.3,4 Despite its remarkable prevalence among the elderly, AD has been regarded 
as a specific disease, distinct from normal aging. This view is supported in large part 
by clinical and pathologic similarities to early-onset, dominantly inherited familial 
AD, where genetic mutations related to amyloids have been identified. There is much 
evidence that early onset (sporadic) AD (LOAD) overlaps with normal aging in many 
clinical and pathologic respects.5 Interestingly, early onset AD accounts only for 5% 
of total AD cases. The majority of AD patients (90%–95%) are LOAD, and it usually 
develops after 65 years of age.6
Pathogenesis
While early onset AD is almost certainly genetically based, there are no specific gene 
mutations that are associated with inheritance of the disease in LOAD. The expres-
sion of the apolipoprotein E (ApoE) 4 allele is one of the risk factors identified for 
LOAD.7 In the central nervous system, ApoE is synthesized by astrocytes, microglia, 
and, to a lesser extent, by neurons. The role of ApoE in LOAD pathogenesis is not 
fully elucidated, but it has been suggested that ApoE is important in trafficking of 
amyloid β (Aβ) peptide.8 In addition, apolipoprotein J (clusterin), an amyloid β-peptide 
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chaperone, TOMM40, a transporter of proteins across the 
mitochondrial membrane, and Sortillin-related receptor, 
which functions to partition amyloid precursor protein away 
from β-secretase and γ-secretase, are recently discovered 
proteins encoded by the risk genes for LOAD.3 In addition to 
nonmodifiable genetic risk factors, potentially modifiable fac-
tors, such as hypertension, diabetes mellitus, hyperlipidemia, 
  hyperhomocysteinemia, coronary and peripheral artery 
  diseases, alcohol, smoking, obesity, levels of physical or men-
tal activity, levels of education, and environmental exposures 
have been investigated to identify risk factors for LOAD.9,10 
Furthermore, it has been reported that risk index methods 
including these risk factors provide a practical, flexible, and 
objective framework for identifying the optimal combina-
tion of measures for identification of high-risk individuals 
for prevention and early intervention efforts.10 Despite the 
personal and societal burden of LOAD, our understanding of 
the genetic predisposition to LOAD and the contribution of 
other risk factors remains limited. More importantly, there are 
few data to explain the overall risks and benefits of prevention 
strategies or their impact on risk modification.9
AD is characterized by extensive atrophy of the brain 
caused by a series neuropathologic changes, including 
neuronal loss, formation of amyloid plaques, appearance of 
neurofibrillary tangles, and synaptic loss.11,12 Amyloid plaques 
and neurofibrillary tangles result from an aberration in depo-
sition of the Aβ peptide and the hyperphosphorylated tau 
protein, respectively, and these depositions lead to neuronal 
loss and neurotoxicity in the brain affected by AD.13 However, 
these changes in the brain are not found throughout the brain 
and preferentially affect specific brain areas in a manner 
that is essentially consistent from patient to patient.14 Data 
obtained by electron microscopy and immunocytochemical 
and biochemical analysis on synaptic marker proteins in 
AD biopsies and autopsies indicate that synaptic loss in the 
hippocampus and neocortex is an early event and the major 
structural correlate of cognitive dysfunction. From all cortical 
areas analyzed, the hippocampus appears to be the most 
severely affected by the loss of synaptic proteins, while the 
occipital cortex is affected least.15 In addition, it was reported 
that synaptic loss is currently the best neurobiologic correlate 
of cognitive deficits in AD. Also, there is evidence that living 
neurons lose their synapses in AD. Furthermore, synaptic 
function is impaired in living neurons, as demonstrated 
by decrements in transcripts related to synaptic vesicle 
trafficking.16
Although new imaging techniques and powerful animal 
models have helped understanding the time course and the 
mechanisms of the lesions, the relationship between Aβ 
  accumulation and tau pathology is still badly understood and 
the mechanism of LOAD continues to be debated. Accumula-
tion of Aβ peptides may be the key event in the pathogenesis 
of AD. The exact mechanism by which Aβ peptide deposition 
induces neurotoxicity is unclear, but it appears that oxidative 
stress plays an important role. Oxidative stress is extensive 
in AD, and Aβ peptides stimulate oxidative stress by both 
direct and indirect mechanisms. Aβ peptides by themselves 
may act as enzymes and can bind to mitochondrial proteins, 
resulting in the generation of free radicals.17,18 Furthermore, 
Aβ peptides generate oxidative stress via   neuroinflammation. 
Considerable evidence has supported the hypothesis that neu-
roinflammation is associated with AD pathology.18 In addition, 
in AD, vascular injury and parenchymal inflammation per-
petuate the cycle of protein aggregation and oxidation in 
the brain, and diffuse pathologic changes include cerebral 
amyloid angiopathy, affecting more than 90% of patients 
with AD, capillary abnormalities, disruption of the blood–
brain barrier, and large-vessel channels.3,19 It has also been 
reported that clearance of Aβ along diseased perivascular 
channels and through the blood–brain barrier is impeded in 
AD atheroma,20 and that deregulation of Aβ transport across 
the capillary blood–brain barrier is caused by the imbalanced 
expression of low-density lipoprotein receptor-related pro-
teins and receptors for advanced glycation end products.19,21 
Furthermore, insulin resistance and hyperinsulinemia are 
implicated in a number of pathophysiologic processes related 
to AD.22,23 It has been demonstrated that reduced brain insulin 
signaling is associated with increased tau phosphorylation 
and Aβ levels in a streptozotocin-induced model of diabetes 
mellitus,24,25 and also that insulin promotes the release of 
intracellular Aβ in neuronal cultures and accelerates Aβ 
trafficking to the plasma membrane. Similarly, intravenous 
insulin infusion also raises plasma Aβ42 levels in patients with 
AD but not in normal adults, an effect that is exaggerated in 
patients with AD and a higher body mass index. In addition, 
impaired insulin or insulin-like growth factor-1 signaling can 
result in hyperphosphorylation of tau, which can cause cell 
death mediated by apoptosis, mitochondrial dysfunction, or 
necrosis, and promote oxidative stress, which contributes 
to the neurodegeneration cascade, and leads to dementia-
associated behavioral and cognitive deficits. For this reason, 
it seems that insulin resistance causes tau phosphorylation, 
neurofibrillary tangle formation, and increased beta amyloid 
aggregation in LOAD.22,23–25 Therefore, we think that the insu-
lin resistance should be taken into account, both in explaining 
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LOAD. In short, the current pathophysiologic approach to 
LOAD is based on a number of common mechanisms of neu-
rodegeneration, including   accumulation of abnormal proteins, 
mitochondrial dysfunction, and   oxidative stress, impaired 
insulin signaling, calcium homeostasis dysregulation, early 
synaptic disconnection, and late apoptotic cell death. Aging 
itself is associated with mild cognitive   deterioration,   probably 
due to subtle multifactorial changes resulting in a global 
decrease of functional brain reserve.3,22,26
Symptoms
AD can affect different people in different ways, but the most 
common symptom pattern begins with gradually worsen-
ing difficulty remembering new information. In the early 
stages, the most commonly recognized symptom is inability 
to acquire new memories, such as difficulty in recalling 
recently observed facts.27 Cognitive profiles of normal aging 
emphasize a decline in skills, including learning efficiency, 
working memory, and psychomotor speed. Although memory 
impairment is the earliest cognitive change in AD, distin-
guishing early disease from normal aging can be difficult, 
and making a decision as to whether a memory complaint is 
associated with the normal aging process or is a precursor 
sign for dementia, is difficult for the doctor.28–30 Therefore, the 
earliest observable symptoms are often mistakenly thought 
to be age-related concerns, or manifestations of stress.31 
When AD is suspected, the diagnosis is usually confirmed by 
behavioral assessment and cognitive tests, often followed by 
a brain scan if possible.31 As the damage spreads, individuals 
also experience confusion, disorganized thinking, impaired 
judgment, trouble expressing themselves, and disorientation. 
The following are warning signs of Alzheimer’s disease:
•	 Memory loss that disrupts daily life
•	 Challenges in planning or solving problems
•	 Difficulty completing familiar tasks at home, at work, or 
at leisure
•	 Confusion in time or place
•	 Trouble understanding visual images and spatial 
relationships
•	 New problems with words in speaking or writing
•	 Misplacing things and losing the ability to retrace steps
•	 Decreased or poor judgment
•	 Withdrawal from work or social activities
•	 Changes in mood and personality.27
As the disease advances, symptoms include confusion, 
irritability, and aggression, mood swings, language 
breakdown, long-term memory loss, and the general 
withdrawal of the sufferer as their senses decline.31 As the 
disease progresses, cognitive impairment becomes profound 
and daily functioning skills decline. Although typically 
thought of as indicative of late-stage disease, behavioral 
symptoms can appear early in the course of the disease, well 
before clinical diagnosis. These symptoms can include social 
withdrawal, depression, paranoia, and mood changes. As the 
disease advances, symptoms such as anxiety, irritability, and 
  agitation become more pronounced.32 Behavioral symptoms 
are also a major source of stress for the caregiver. Behavioral 
disturbances have been shown to be a strong predictor of 
caregiver burden8 and are associated with increased financial 
hardship for the caregiver.33 Physical functions are gradually 
lost, ultimately leading to death. Individual prognosis is 
difficult to assess, because the duration of the disease varies. 
AD develops for an indeterminate period of time before 
becoming fully apparent, and it can progress undiagnosed 
for years. The mean life expectancy following diagnosis is 
approximately 7 years.34 Fewer than 3% of individuals live 
more than 14 years after diagnosis.35
Diagnosis
There is an increasing interest in the identification of patients 
in the earliest stage of AD, prior to clinical manifestation of 
dementia, in order to provide effective early intervention 
that aims at delaying significant impairment. A definitive 
diagnosis of AD requires a detailed post-mortem micro-
scopic examination of the brain. But nowadays, AD can be 
diagnosed with more than 95% accuracy in living patients 
by using a combination of tools. These include taking a care-
ful history from patients and their families, and assessing 
cognitive function by neuropsychologic tests. Other causes 
of dementia must be ruled out, such as low thyroid function, 
vitamin deficiencies, infections, cancer, and depression. It is 
also crucial to differentiate AD from other neurodegenera-
tive dementias.36
The National Institute of Neurological and Communica-
tive Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) and the 
Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Text Revision (DSM-IV-TR) criteria for AD 
are the prevailing diagnostic standards in research. However, 
they have now fallen behind the unprecedented growth of 
scientific knowledge. Moreover, NINCDS-ADRDA was 
reported in 1984 and the subsequent DSM-IV-TR in 2000. 
For this reason, to improve the specificity for diagnosis of AD, 
the criteria were revised by Dubois to offer a new diagnostic 
approach including genetic testing, molecular imaging, and 
body fluid biomarkers.37 Furthermore, draft reports presented Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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at the International Conference on Alzheimer’s Disease in 
2010 will form the basis of new diagnostic criteria for mild 
cognitive impairment and AD.
Treatment
There was no effective therapy for AD before the approval 
of the cholinesterase inhibitors and memantine. These 
agents are associated with detectable symptomatic improve-
ment, and have a modest effect on the progression of AD 
from mild cognitive impairment to disabling dementia and 
death.38 Medicines currently prescribed for AD fall into three 
groups, ie, inhibitors of acetylcholinesterase (according to 
the cholinergic hypothesis of AD, memory impairments 
result from death of cholinergic neurons in the basal fore-
brain), an antagonist of a receptor for the neurotransmitter 
glutamate, and drugs from the psychiatric toolbox to control 
depression and behavioral abnormalities.36
The clinical development of new agents for symptomatic 
and disease-modifying treatment of AD has resulted in both 
promise and disappointment. Despite the fact that no new 
compound for the treatment of AD has been introduced 
since the approval of memantine in 2002, the variety of drug 
targets and mechanisms of action, and the total number of 
compounds under investigation make it highly likely that 
important new pharmacotherapeutic options will become 
available for the treatment of AD over the next decade. 
Moreover, research into the underlying etiology and 
pathophysiology of AD is likely to facilitate identification 
of additional targets for future drug development.38 In 
addition, stem cell therapy for AD might be used to replace 
destroyed neurons, but AD poses particular challenges 
in this regard because it affects diverse types of neurons 
in different brain regions.36 However, our experience has 
demonstrated that mesenchymal stem cell therapy might 
provide neuronal replacement and improved cognitive func-
tion in streptozotocin-induced neurodegeneration in rats, 
but adjunctive therapies with mesenchymal stem cells in 
this type of neurodegeneration need to be tried.39 However, 
the development of bone marrow mesenchymal stem cell 
therapy for the replacement of cells and tissues lost due to 
neurodegeneration in AD is still in the early stages, and fur-
ther studies will be needed before it can be tested in humans. 
Nonetheless, these improving effects of mesenchymal stem 
cells give us hope for the future.
Prevention
Nowadays, there is no definitive evidence to support any 
particular measure being effective in prevention of AD. 
Global studies of measures to prevent or delay the onset 
of AD have often produced inconsistent results. However, 
epidemiologic studies have proposed relationships between 
certain modifiable factors, such as diet, cardiovascular risk, 
pharmaceutical products, or intellectual activities, among 
others, and a population’s likelihood of developing AD. Only 
further research, including clinical trials, will reveal whether 
these factors can help to prevent AD.40 In addition, at the 
International Conference on Alzheimer’s Disease in 2010, 
it was also reported that moderate to heavy physical activity 
is associated with a reduced risk of dementia, with up to two 
decades of follow-up.41
Conclusion
In summary, AD is increasingly being diagnosed as one of 
the most important medical problems in the elderly, and 
the management of elderly patients with AD is complex. 
A comprehensive approach is required that focuses on 
both the patient and caregiver. Despite all developments, 
our treatment options for prevention and treatment of the 
  cognitive, behavioral, and psychologic symptoms of AD 
are still lacking. Therefore, it is important for clinicians to 
recognize early signs and symptoms of AD and to determine 
potentially modifiable risk factors.
Disclosure
The author reports no conflicts of interest in this work.
References
  1.  Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact 
of Alzheimer’s disease, 2000–2050: Potential implication of treatment 
advances. Annu Rev Public Health. 2002;23:213–231.
  2.  Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the 
“common” neurologic disorders? Neurology. 2007;68:326–337.
  3.  Querfurth HW, LaFerla FM. Mechanisms of disease: Alzheimer’s 
disease. N Engl J Med. 2010;362:329–344.
  4.  den Dunnen WF, Brouwer WH, Bijlard E, et al. No disease in the brain 
of a 115-year-old woman. Neurobiol Aging. 2008;29:1127–1132.
  5.  Drachman DA. Aging of the brain, entropy, and Alzheimer disease. 
Neurology. 2006;67:1340–1352.
  6.  Harman D. Alzheimer’s disease pathogenesis: Role of aging. Ann N Y 
Acad Sci. 2006;1067:454–460.
  7.  Schellenberg GD. Genetic dissection of Alzheimer’s disease, 
a heterogeneous disorder. Proc Natl Acad Sci U S A. 1995;92: 
8552–8559.
  8.  Holtzman DM. Role of ApoE/Aβ interactions in the pathogenesis of 
Alzheimer’s disease and cerebral amyloid angiopathy. J Mol Neurosci. 
2001;17:147–155.
  9.  Patterson C, Feightner JW, Garcia A, et al. Diagnosis and treatment of 
dementia: 1. Risk assessment and primary prevention of Alzheimer 
disease. CMAJ. 2008;178:548–556.
  10.  Barnes DE, Covinsky KE, Whitmer RA, et al. Commentary on 
  “Developing a national strategy to prevent dementia: Leon Thal 
  Symposium 2009.” Dementia risk indices: A framework for identify-
ing individuals with a high dementia risk. Alzheimers Dement. 2010;6: 
138–141.Clinical Interventions in Aging
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal
Clinical Interventions in Aging is an international, peer-reviewed journal 
focusing on evidence-based reports on the value or lack thereof of treat-
ments intended to prevent or delay the onset of maladaptive correlates 
of aging in human beings. This journal is indexed on PubMed Central, 
MedLine, the American Chemical Society’s ‘Chemical Abstracts 
Service’ (CAS), Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
311
Late onset Alzheimer’s disease
  11.  Bussiere T, Giannakopoulos P, Bouras C, et al. Progressive degeneration 
of nonphosphorylated neurofilament protein-enriched pyramidal 
neurons predict cognitive impairment in Alzheimer’s disease: Stereo-
logic analysis of prefrontal cortex area. J Comp Neurol. 2003;463: 
281–302.
  12.  Garry LW. Neuropathologic changes in Alzheimer’s disease: Potential 
target for treatment. J Clin Psychiatry. 2006;67 Suppl 3:3–7.
  13.  Cotman CW, Su JH. Mechanisms of neuronal death in Alzheimer’s 
disease. Brain Pathol. 1996;6:493–506.
  14.  Braak H, Braak E. Neuropathologic staging of Alzheimer-related 
changes. Acta Neuropathol (Berl). 1991;82:239–259.
  15.  Arendt T. Synaptic degeneration in Alzheimer’s disease. Acta 
  Neuropathol. 2009;118:167–179.
  16.  Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer’s disease. 
  Neurobiol Aging. 2003;24:1023–1027.
  17.  Lustbader JW, Cirilli M, Lin C. ABAD directly links Abeta to mitochon-
drial toxicity in Alzheimer’s disease. Science. 2004;304:448–452.
  18.  Newman M, Musgrave FI, Lardelli M. Alzheimer disease: Amyloido-
genesis, the presenilins and animal models. Biochimica Biophysica 
Acta. 2007;1772:285–297.
  19.  Weller RO, Boche D, Nicoll JAR. Microvasculature changes and cerebral 
amyloid angiopathy in Alzheimer’s disease and their potential impact 
on therapy. Acta Neuropathol. 2009;118:87–102.
  20.  Price JM, Chi X, Hellermann G, Sutton ET. Physiological levels of 
beta-amyloid induce cerebral vessel dysfunction and reduce endothelial 
nitric oxide production. Neurol Res. 2001;23:506–512.
  21.  Deane R, Zlokovic BV . Role of the blood-brain barrier in the pathogen-
esis of Alzheimer’s disease. Curr Alzheimer Res. 2007;4:191–197.
  22.  Isik AT, Bozoglu E. Insulin resistance in Alzheimer’s disease. In: Aucoin L, 
Prideux T, editors. Handbook of Type 1 Diabetes Mellitus: Etiology, Diag-
nosis, and Treatment. Hauppauge, NY: Nova Science; 2010.
  23.  Isik AT, Celik T, Ulusoy G, et al. Curcumin ameliorates impaired insulin/
IGF signaling and memory deficit in streptozotocin treated rat model. 
Age. 2009;31:39–49.
  24.  Jolivalt CG, Lee CA, Beiswenger KK, et al. Defective insulin signaling 
pathway and increased glycogen synthase kinase-3 activity in the brain 
of diabetic mice: Parallels with Alzheimer’s disease and correction by 
insulin. J Neurosci Res. 2008;86:3265–3274.
  25.  de la Monte SM, Wands JR. Review of insulin and insulin-like 
growth factor expression, signaling, and malfunction in the central 
nervous system: Relevance to Alzheimer’s disease. J Alzheimers Dis. 
2005;7:45–61.
  26.  Popescu BO, Toescu EC, Popescu LM, et al. Blood-brain barrier altera-
tions in ageing and dementia. J Neurol Sci. 2009;283:99–106.
  27.  Alzheimer’s Association. 2010 Alzheimer’s disease facts and figures. 
Alzheimers Dement. 2010;6:158–194.
  28.  Salthouse TA. Memory aging from 18 to 80. Alzheimer Dis Assoc 
Disord. 2003;17:162–167.
  29.  Treitz FH, Heyder K, Daum I. Differential course of executive con-
trol changes during normal aging. Neuropsychol Dev Cogn B Aging 
  Neuropsychol Cogn. 2007;14:370–393.
  30.  Isik AT. Approach the elderly patient with forgetfulness. Journal of 
Geriatrics and Geriatric Neuropsychiatry. 2009;2:33–38.
  31.  Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis 
and management of Alzheimer’s disease and other disorders associated 
with dementia: EFNS guideline. Eur J Neurol. 2007;14(1):e1–e26.
  32.  Jost BC, Grossberg GT. The evolution of psychiatric symptoms in 
Alzheimer’s disease: A natural history study. J Am Geriatr Soc. 1996;44: 
1078–1081.
  33.  Beier MT. Treatment strategies for the behavioral symptoms of 
Alzheimer’s disease: Focus on early pharmacologic intervention. 
Pharmacotherapy. 2007;27(3):399–411.
  34.  National Institute on Aging. Understanding stages and symptoms 
of Alzheimer’s disease. 2007. Available at: http://www.nia.nih.gov/
alzheimers/publications/stages.htm. Accessed 2008 Feb 21.
  35.  Mölsä PK, Marttila RJ, Rinne UK. Long-term survival and predictors 
of mortality in Alzheimer’s disease and multi-infarct dementia. Acta 
Neurol Scand. 1995;91:159–164.
  36.  Mucke L. Alzheimer disease. Nature. 2009;461:895–897.
  37.  Dubois B, Feldman F, Jacova C, et al. Research criteria for the diagnosis 
of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet 
Neurol. 2007;6:734–746.
  38.  Sabbagh NM. Drug development for Alzheimer’s disease: Where are 
we now and where are we headed? Am J Geriatr Pharmacother. 2009; 
7:167–185.
  39.  Isik AT, Celik T, Ural AU, Tosun M, et al. Does the mesenchymal stem 
cell therapy improve the streptozotocin induced neurodegeneratıon in 
rats? Alzheimers Dement. 2010;6 Suppl 1:569.
  40.  Szekely CA, Breitner JC, Zandi PP. Prevention of Alzheimer’s disease. 
Int Rev Psychiatry. 2007;19:693–706.
  41.  Tan ZS, Beiser AS, Au R, et al. Physical activity and risk of dementia: 
The Framingam study. Alzheimers Dement. 2010;6 Suppl 1:S68.